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Objective: Consumption of crude natural products like plants and herbs for mitigation or treatment of illnesses usually accompanied with 
inconsistent therapeutic effects because of poor solubility and low bioavailability of active phytochemical(s) in addition to product instability. To 
overcome all of above mentioned drawback ethanol extract of Moringa oleifera leaf was formulated as standardised solid dosage form.  
Methods: Different types of materials as an adsorbent, surfactant and other necessary excipients were tested to be use in formulation of Moringa 
granules utilising wet granulation method. The formulated Moringa granules was then evaluated for organoleptic properties and physical 
characteristics, in vitro dissolution test, compatibility, drug content, heavy metal tests and microbial limit tests. Additionally, the in vivo anti-
inflammatory against Carrageenan-induced paw oedema and anti-arthritic activity against CFA-induced arthritis were also assessed.  
Results: 95% ethanol extract of M. oleifera leaves was successfully formulated as standardised granules for oral administration utilising simple and low-
cost techniques. Dissolution rate for the marker compounds was increased by an average of 1.076 fold. Animal groups given the prepared Moringa 
granules showed an improvement in the anti-inflammatory activity and the anti-arthritic activity compared to animal groups given crude extract at the 
same dose level. Additionally, all the treatment groups showed a significant difference at P<0.05 and P<0.01 compared to control group.  
Conclusion: To the best of our knowledge, this work was the first to use gum Arabic in the formulation of a standardised botanical pharmaceutical 
dosage form of M. oleifera crude extract. Additionally, formulation of Moringa granules apparently improves the drug release profile and bioactivity 
compare to Crude Moringa extract. 
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INTRODUCTION 
The interest in botanical products has been regenerated because of 
the discovery of many novel natural bioactive phytochemicals [1]. 
However, the therapeutic potential of these compounds is often 
limited by their poor solubility, low bioavailability and product 
instability [2]. In this regard, pharmaceutical scientists should 
explore delivery systems that can enhance drug solubility and 
bioavailability and improve product stability. The complexity of 
phytoconstituents and the indecision about the phytochemical(s) 
responsible for bioactivity are the most challenging problems in 
formulation and evaluation of herbal products. 
Moringa oleifera Lam is well-known and most widely cultivated 
species of Moringaceae, which is a mono-generic flowering plant 
family that comprises 13 species. M. oleifera has been founded in 
many tropic and sub-tropic regions worldwide. The plant is referred 
to by a number of names such as horseradish tree, drumstick tree, 
ben oil tree, miracle tree, and “Mother’s Best Friend”. The leaf of M. 
oleifera is the most valuable part of the plant used as food and 
traditional medicine source. Large number of nutrients as such 
proteins, minerals and fibres that affords an important role in the 
human diet as well as it is a valuable nutritive, healing and 
socioeconomic potentials [3]. An online survey indicates a large 
number of M. oleifera medicinal and dietary supplement products, 
alone or in herbal combinations, available in the global markets. The 
products are mostly in oral dosage form as tablets, capsules, tea 
bags, elixir, syrup and leaf powder for decoction. Our survey and that 
conducted by [4] revealed that almost all of the reviewed products 
shared one or more features of the following variable in product 
composition, not standardised against a bioactive phytochemical 
marker(s) and inconsistence in medicinal indications and uses 
despite originating from the same plant part and using the same 
dose strength and same manufacturing processes. 
In this study, an ethanol extract of M. oleifera leaves had been 
formulated as a standardised granules, evaluated for their 
organoleptic properties, physical and chemical characteristics, and 
subjected to in vitro dissolution test. Additionally, in vivo 
bioactivity of the formulated granules as anti-arthritis and anti-
nociceptive were also evaluated. To the best of our knowledge, this 
the first time that ethanol extract of Moringa oleifera leaves was 
formulated as a solid dosage form with standardised content of 
marker compounds, standardised drug release rate and improved 
bioactivity. 
MATERIALS AND METHODS 
Chemicals and reagents 
Astragalin (Kaempferol-3-O-glucoside) 98% purity, Extrasynthese 
(Genay, France); Cryptochlorogenic acid (4-O-Caffeoylquinic acid) 
98% purity, Chemfaces (Wuhan, China); Ethanol 95%, Fisher Scientific 
(Selangor, Malaysia). λ-Carrageenan, Indomethacin, Complete Freund’s 
Adjuvant (CFA) (1  mg/ml) of heat killed dried M.  tuberculosis (strain 
H37Ra, ATCC  25177) suspended in 1.5 ml mannide  monooleate and 
8.5 ml, and Tween (Polysorbate) 20, 40, and 80all purchased from 
Sigma-Aldrich, St., MO, USA. Gum Arabic and HPMC, Methocel K100M 
CR were purchased from Colorcon Ltd, New Hampshire, USA. 
Magnesium stearate, RandM Marketing, Essex, UK; Microcrystalline 
cellulose (Avicel  PH200) 200 , FMC BioPolymer, Newark DE, USA.   
Equipment and instruments 
BUCHI R-114 rotary vacuum evaporator, BUCHI Labortechnik AG 
(Flawil, Switzerland); Drying oven, Memmert GmbH and Co. 
(Schwabach,  Germany);  Shimadzu HPLC system, Shimadzu 
Corporation (Kyoto, Japan) ; Digital micrometer, Mitutoyo, ID-
C1012EXBS,  Kawasaki, Japan; Electrolab ETD-1020 Tap Density 
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 Tester  (Globe-Pharma) Ireland; Fourier-transform infrared 
 spectrometer Thermo Nicolet Nexus 470, USA. 
Authentication of plant materials 
The plant was authenticated by Dr. R. Zakaria, Plant Sciences; and 
sample was reserved in the herbarium of the School of Biological 
Sciences, Universiti Sains Malaysia (USM) under a voucher specimen 
No. 11626 
Formulation of Moringa granules (Moringa-G) 
The 95% ethanol extract of M. oleifera leaves prepared by 
maceration of dried, pulverised leaves in 95% ethanol at ratio of 1:5 
and temperature of 45 °C for 72 h. The collected extract was first 
filtered using Whatman No.1 filter paper, concentrated using rotary 
evaporator then dried in drying oven at 45 °C for 48h. The obtained 
dry extract was formulated as common granules using wet 
granulation method. Selection of surfactant and adsorbent agent 
were based on the results obtained from preformulation studies of 
95% ethanol extract of M. oleifera leaves [5]. Ethanol (95% v/v) was 
used as wetting agent enough to made Moringa extract as a paste. 
Tween 20 and gum Arabic were added and kneaded. The prepared 
mixture then speared on stainless steel tray and dried in drying oven 
at 45 °C for 48 h. The dried mass was screened through sieve No.22 
(0.8 mm) and dried again in drying oven at 45 °C for 24 h and 
screened through sieve No. 35 (0.5 mm). The collected granules then 
evaluated.  
Organoleptic properties and physical characteristics  
The formulated Moringa-G were evaluated for their organoleptic 
properties, namely, appearance, colour, odour and taste. Particle size 
distribution was assessed using the sieve method. Loss on drying at 
65 °C, the pH of 1% (w/v) solution at 25 °C and reconstitution time 
were determined as described by [6]. 
Angle of repose 
A stainless-steel funnel with a 10 mm orifice diameter and 111 mm 
length from the top to the end of the orifice was fixed at 4 cm from 
the bench to the funnel orifice. In brief, 5 g of powder sample was 
charged into the funnel and allowed to fall. The height (h) and width 
(w) of the pile were measured. The results were considered valid 
only when a symmetric cone was obtained. The procedure was 
repeated in triplicate. Angle of repose (θ) was calculated as follows:  
𝜽 = 𝒕𝒂𝒏−𝟏 �
𝒉
𝟎.𝟓𝒘
�… … .𝑬𝒒. (𝟏) 
Bulk density and tapped density 
In brief, 10 g sample was transferred into a 25 ml graduated cylinder 
with 0.5 ml mark. The cylinder was manually tapped gently twice on 
a table top surface, and the volume was measured. Bulk density was 
calculated as follows:  
ρbulk = W
vb 
 ………. Eq. (2) 
Where w is the weight of the sample, and Vb
The cylinder was fixed to the tap density tester and subjected to 500, 
750 and 1250 taps at a rate of 250 taps/min. After each specified 
number of taps, the tapped volume was measured. Tapped density 
was calculated as follows:  
 is the volume occupied 
by the bulk powder. 
ρtapped = W
vt 
 ………. Eq. (3) 
Where w is the weight of the sample, and Vt
Carr’s compressibility index and Hausner’s ratio 
 is the volume occupied 
by the powder after tapping. 
The results of bulk and tapped densities were used to calculate 
Carr’s compressibility index (Eq. 4) and Hausner’s ratio (Eq. 5). 
These parameters help in estimating the flow properties and 
compressibility of the powder. 
CI = ρtapped − ρbulk
ρtapped




. . Eq. (5) 
In vitro drug dissolution and drug release profile 
In vitro drug dissolution was determined using USP-apparatus II (paddle 
apparatus). The samples of Moringa-G and M. oleifera crude extract were 
immersed in 500 ml of distilled water as dissolution medium at 37±0.5 
°C and paddle speed of 100 revolutions per minute. Six dosage units 
were individually placed in each of the six vessels of the dissolution 
apparatus. Aliquots of the dissolution medium (3 ml) from each of the six 
vessels were withdrawn on 5, 15, 30, 45, 60, 90, 120 and 180 min, 
combined and filtered with a 0.45 mm syringe filter to achieve a pooled 
sample that will be used as test samples. The volume of the dissolution 
medium was kept constant by adding 3 ml of the solution pre-heated to 
37 °C to fresh distilled water after each withdrawal. The samples were 
analysed for drug concentration using HPLC method described by [5]. 
Percent cumulative drug release for Moringa-G and M. oleifera crude 
extract were calculated and plotted against time. Graphical analysis 
method was used for comparison of the dissolution pattern, and the 
reference markers concentrations at each time point were used to 
compare the extent of dissolution. Percent dissolution efficiency (%DE) 
was used to characterise the release profile. DE can be calculated using 
the following equation:  
DE% = �
∫ y × dtt2t1
y100 × (t2 −  t1)
�  ×  100. . Eq. (6) 
Where y is the percent dissolved reference marker at specified time 
and y100 
Compatibility of excipients 
is the maximum dissolution percent. 
Fourier-transform infrared (FT-IR) spectroscopy analysis of 95% 
ethanol extract of M. oleifera leaves and formulated Moringa-G were 
conducted to evaluate drug-excipient compatibility. In brief, a 1% 
mixture of 95% ethanol extract of M. oleifera leaves/Moringa-G with 
IR-grade potassium chloride was prepared as disc and analysed by 
FT-IR spectroscopy with single-reflection ATR attachment within the 
IR range of 400 cm-1to 3000 cm-1
Drug content  
.  
Drug content was calculated using HPLC method described by [4]. 
The test solution was prepared by accurately weighed a portion of 
prepared Moringa-G equivalent to 100 mg of M. oleifera extract, 
dissolved in 10 ml of 50% methanol, sonicated and filtered using 
0.45 mm syringe filter to obtain 10 mg/ml solution. A standard 
calibration curve was plotted and mean drug content (%) was 
calculated as the average of three determinations (n=3).  
Microbial limit tests 
Microbial limit test was conducted to quantitatively estimate the total 
number of aerobic microorganisms, total yeasts and moulds, bile-
tolerated Gram-negative bacteria, Salmonella sp., Escherichia coli, 
Staphylococcus aureus and Pseudomonas aeruginosa in accordance with 
[7], Appendix XVIB. The test microbes used in determination of 
microbial limit test were obtained from School of Biology, USM, Malaysia. 
Heavy metals test 
Heavy metal analysis was conducted as described by [7], Appendix 
IID. Inductively coupled plasma–atomic emission spectroscopy (ICP-
AES) technique was used to determine the levels of cadmium, 
arsenic, lead and mercury. 
Animal ethics and laboratory animal  
Animal’s experimental protocol was approved by Animal Ethics 
Committee of Universiti Sains Malaysia No.: USM/Animal Ethics 
Approval/2016/(103) (764) and USM/Animal Ethics 
Approval/2016/(103)(807). Healthy male Sprague-Dawley rats 8-
10 w old and weighing 150-180 g were used. They were fed with 
standard pellet diet and free access to water. They were housed in 
polypropylene cages, 3 animals per cage maintained under 12 hour 
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light, 12 hour dark cycle; 27±3 ̊C, 45 %±5% relative humidity and 
allowed to acclimatise for 7 d before starting the experiments.  
In vivo anti-inflammatory activity  
The anti-inflammatory activity of Moringa-G was assessed using 
Carrageenan-induced paw oedema method and the selection of the 
administered dose was as described by [8]. The animals were fasted 
12 h before experiment, but provided with water ad libitum. The rats 
were randomly assigned into four groups of six animals each (n = 6), 
weighed and numbered. Group I was the disease control group given 
only distilled water. Group II was orally treated with indomethacin 
(5 mg/kg body weight). Group III was orally treated with M. oleifera 
crude extract at a dose of 250 mg/kg body weight and group IV was 
orally treated with Moringa-G at dose equivalent to 250 mg/kg body 
weight. After 1 h of oral dose treatment, inflammatory paw oedema 
was induced by injecting 0.1 ml of freshly prepared 1% (w/v) 
carrageenan in normal saline into the sub-plantar region of the left 
hind paw of the rats. The thickness of the left hind paw was 
measured using a digital micrometre immediately before and at 1, 2, 
3, 4 and 5 h after the carrageenan injection. The anti-inflammatory 
activity of M. oleifera crude extract and Moringa-G were calculated as 
percent increase in paw oedema by using the formula:  
% increase in paw oedema = A−B 
B
 × 100………. Eq. (7) 
Where A is the paw thickness at the respective hours, and B is the 
paw thickness at hour 0 of the experiment. The results were 
expressed as mean % oedema±standard error of the mean (SEM) of 
six animals per group and statistically analysed compared with the 
disease control group. 
In vivo activity against CFA-induced rheumatoid arthritis  
Animals and experimental design 
The animals were randomly designed into five groups of five animals 
per group (n = 6). Group I: (Normal control) without CFA injection 
and treatment; group II: (CFA-control) CFA injection and vehicle 10 
ml/kg/day; group III: CFA injection and oral treatment with 
indomethacin at 2.5 mg/kg/day; group IV: CFA injection and oral 
treatment with 250 mg/kg/day M. oleifera extract and group V: CFA 
injection and orally treated with Moringa-G at dose equivalent to 
250 mg/kg/day. The daily oral dose for groups II to V were 
administered at 9 am and continued to day 21 post-injection. 
Measurements were conducted at 2 pm.  
Induction of arthritis 
Immunological arthritis was induced using the method described by 
[9]. The hind limbs of rats in groups II to V were shaved and 
sterilised with 70% (v/v) alcohol. Subsequently, 0.1 ml of CFA 
containing 1 mg/ml heat-killed M. tuberculosis were injected into the 
sub-plantar area of the left hind paw of each animal under mild 
anaesthesia with diethyl ether. The time of CFA injection was 
referred to as day 0.  
Assessment of rheumatoid arthritis 
CFA-induced arthritic paw oedema  
The thickness of the left and right hind paws was recorded on day 0 
before the induction of arthritis with CFA and considered as a 
baseline. The thickness of the paws was measured again on days 3, 6, 
9, 12, 15, 18 and 21 post-CFA injection using a digital micrometre 
gauge. The percent increase in paw oedema was calculated using 
equation (7). 
Change in animal’s body weight  
The body weight of the animals was monitored starting from day 0 
and repeated on days 3, 6, 9, 12, 15, 18 and 21 post-CFA injection. 
Percent weight change was calculated using the following formula:  




Where Wt is the weight of the animal at time t, and Wo 
Arthritic index 
is the weight 
of the animal on day 0. The calculated weight change in the 
treatment groups was statistically compared with those in normal 
control and CFA-control groups. 
Arthritic index is a numeric system used to score the severity and 
disease progression of CFA-induced immunological arthritis. 
Development and severity of induced RA in rats were evaluated by 
a visual scoring system of the clinical signs and symptoms on a 
scale of 0–4 per limb by using the method described by [10] where 
0: no change, 1: slight swelling and erythema of the finger, 2: 
swelling of the phalanx joint and digits, 3: severe swelling of the 
entire paws, and 4: deformity or ankylosis. The scores for the left 
and right hind limbs were combined, and the maximum score was 
8. A score of 1 and above indicates arthritis. Measurement was 
started on day 3 post-CFA injection to avoid the pre-acute phase of 
CFA and then repeated on days 6, 9, 12, 15, 18 and 21 post-
injection. 
Walking track analysis  
Walking track analysis was initially described by [11] as an 
approach to analyse changes in locomotion and functional 
behaviour. The footprints of each rat were recorded by immersing 
their hind paws in the ink and allowing them to walk over a paper 
sheet (8.7 cm wide by 43 cm long) fixed on a confined walkway 
corridor, with a dark shelter at the end. After two or three 
conditioning trials, when the rats were often stopped to explore the 
corridor, they began to walk steadily to the dark shelter end. The 
procedure was repeated on day 0 before CFA injection and on days 
14 and 21 post-injection. The obtained data from the rat’s footprint 
were used to calculate the functional index (FI) by using the 






EPL � + �
ETS − NTS





where ETOF and NTOF are experimental (injected paw) and normal 
paw distance, respectively, to the opposite foot (mm); EPL and NPL 
are experimental and normal paw print length (mm), respectively; 
ETS and NTS are experimental and normal total paw spreading 
(mm), respectively; and EIT and NIT are experimental and normal 
intermediary toe spreading (mm), respectively. In the normal value 
range (±11%), 0 represents a totally normal paw and 100 represent 
a totally impaired paw. 
 
 
X-ray radiographic assessment 
 
On day 21 post-CFA injection, radiographs were taken with X-ray 
apparatus (PHILIPS Diagnose X-ray) at 55 kVp and 3 mA with focal 
film distance of 60 cm. The severity of joint deformation was blindly 
scored in accordance with the extent of oesteoporosis, joint spaces, 
soft tissue inflammation, subchondral erosion and joint ankylosis on 
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a scale of 0–4 as described by [10]; the scores are as follows: 0: no 
soft tissue inflammation and no degenerative joint changes; 1: slight 
soft tissue inflammation, joint space, subchondral erosion, 
oesteolysis and degenerative joint changes, 2: moderate soft tissue 
inflammation, joint space, subchondral erosion, oesteolysis and 
degenerative joint changes; 3: marked soft tissue inflammation, joint 
space, subchondral erosion, oesteolysis and degenerative joint 
changes; and 4: severe soft tissue inflammation, joint space, 
subchondral erosion, oesteolysis and degenerative joint changes. 
The X-ray images were analysed and scored independently by two 
certified radiologists who were blinded to the groups.  
Haematology profile 
On day 22 post-CFA injection, 4.5 ml of blood was collected from 
each animal through cardiac puncture under mild anaesthesia with 
diethyl ether and placed in suitable blood collection tubes (BD 
Vacutainer®). Haematological parameters including haemoglobin 
content (HGB), total red blood cell count (RBC), percent packed cell 
volume (% PCV) and total white blood cell count (WBC) were 
evaluated immediately after blood sample collection by using an 
automated haematology analyser (Beckman Coulter Blood 
Analyser). Erythrocyte sedimentation rate (ESR) was determined 
using the Westergren capillary tube method described by Guha et al. 
(2014).  
Data analysis 
The data obtained from in vivo experiments were expressed as 
mean±SEM; while other data were expressed as mean±SD. Statistical 
difference between means was analysed by IBM-SPSS version 20 
software by using one-way ANOVA followed by post hoc Dunnett–t 
test (2-tailed) at different variance levels. 
RESULTS AND DISCUSSION 
Selection of adsorbent 
The sticky, greasy texture of the M. oleifera extract requires the use 
of a suitable adsorbent to convert it into non-stick, freely flowable 
granules. Various adsorbents, natural or synthetic, were tested at the 
ratio of 1:1 to convert the M. oleifera extract into powder form (table 
1). Three adsorbents showed a promising results, i.e. Avicel PH101, 
PVP-K12.5 and gum Arabic. For the three selected adsorbents, 
different ratios of adsorbents to the M. oleifera extract were tested 
(i.e. 0.5:1, 0.6:1 and 0.75:1) to determine the lowest useful ratio. 
 
Table 1: Description of the granules when different adsorbents were mixed with 95% ethanol extract of M. oleifera leaf at 1:1 ratio 
Adsorbent Description 
Avicel PH 200 
Avicel PH101 
Good shape coarse granules, dark green colour and need long drying time. 
Good shape green colour granules.  
Lactose monohydrate Sticky soft very dark green colour mass and cannot be shaped as granules.  
Starch (maize) Soft light green colour mass and cannot be shaped as granules.  
β-cyclodextrin Sticky soft dark green mass and cannot be shaped as granules.  
PVP-K12.5 Good shape green granules, hygroscopic during storage.  
Gum Arabic Good shape very dark green granules.  
The prepared mixtures were evaluated for their flow properties and bulk and tapped densities (table 2). On the basis of the results of the angle of 
repose and density, gum Arabic was selected as the adsorbent to be applied at an adsorbent-to-M. oleifera extract ratio of 0.6:1. 
 
Table 2: Evaluation of lowest ratio of adsorbents to M. oleifera extract for their flowability and density per adsorbent 
Adsorbent Lowest ratio Angle of repose Bulk density Tapped density Hausner’s ratio 
Avicel PH101 0.6:1 30.191±0.083 0.323±0.003 0.3488±0.0667 1.0788 
Gum Arabic 0.6:1 33.690±0.112 0.4046±0.201 0.4563±0.412 1.1277 
PVP-K12.5 0.75:1 37.364±0.0642 0.3448±0.0938 0.3726±0.113 1.0806 
*Results were expressed as (mean±SD, n=3). 
 
Selection of surfactant 
Different types of surfactants, anionic and non-ionic, (Poloxamer 
407, sodium lauryl sulphate, Tween 20, Tween 40, Tween 80, Span 
20 and Span 40) were tested. Evaluation of the tested surfactants 
showed that Tween 20 was the best surfactant that improved the 
solubility of the M. oleifera extract. Tween 20 is a polyoxyethylene 
sorbitan monolaurate, that is, an amphipathic surfactants 
composed of fatty acid esters of polyoxyethylene sorbitan. Their 
popularity is largely due to their effectiveness at low 
concentrations and relatively low toxicities with an acceptable 
daily intake is up to 25 mg/kg body weight [12]. In addition, these 
surfactants are also widely used in the food industry because of 
their excellent emulsifying properties. Surfactant molecules form 
associates in the aqueous/non-aqueous solution beyond a certain 
concentration called micelles. The shape and size of the micelles 
are affected by many factors including temperature and 
concentration of surfactant. The consumption of missiles in the 
form of drug carriers is more valuable than other types of carriers 
owing to their tiny mass (~10–30 nm) and the enhanced stability 
of the drug in the course of missiles inclusion [13]. Accordingly, 
Tween 20 was selected to be used in the formulation of Moringa-G. 
Different concentrations of Tween 20 were then tested to 
determine the lowest useful concentration, which turned out to be 
1% (w/w). Tween 20 was miscible with Moringa crude extract and 
other added excipients and can also improve bioavailability by 
acting as a P-glycoprotein inhibitor [14]. Identifying the solubility 
extent is important in determining the need for additional 
improvement steps.  
Preparation of Moringa granules 
On the basis of the results of the test adsorbents and surfactant agents 
above, gum Arabic was selected as adsorbent and Tween 20 was 
selected as surfactant for preparation of Moringa granules. The granules 
were prepared through wet granulation at a dose size of 3 g/dose as 
described by [8] to be the minimum effective dose. No need for adding 
preservative as ethanol extract of M. oleifera leaves was known for its 
antimicrobial activity against wide range of microorganisms [15]. In 
addition to that, usually alcoholic extract in contrast to aqueous extract 
does not need for preservatives or a stabilizer [16, 17]. 
Organoleptic properties and physical characteristics of the 
prepared Moringa granules (Moringa-G) 
The prepared Moringa-G was evaluated for organoleptic properties, 
including appearance, colour, odour and taste (table 3). Particle size 
distribution was slightly wide in range due to the use of manual 
granulation.  
Loss on drying as within the acceptable limit of USP37-NF32 (2014). The 
powder flowability test results, including angle of repose, Hausner’s ratio 
and Carr’s index, indicate the good flowability of the granules. 
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FT-IR spectroscopy of Moringa-G 
The FT-IR spectra of the 95% ethanol extract of M. oleifera leaves 
and the prepared Moringa-G showed the compatibility of the used 
excipients with the extract (fig. 1). All the major peaks of the M. 
oleifera extract and Moringa-G were present. The spectra did not 
show additional peaks, shifts or disappearance of characteristic 
peaks. This result confirms the absence of any chemical or physical 
interaction between the M. oleifera extract and excipients used for 
granule preparation. 
 
Table 3: Organoleptic properties and physical characteristics for the prepared Moringa granules 
Parameter Result 
Appearance Coarse granules not stick to container wall or aggregate together with acceptable shape 
Colour Very dark green 
Odour Faint characteristic odour 
Taste Slight bitter pungent taste 




Loss on drying (%) at 65 °C 0.428% 
pH of 5% aqueous solution at 25 °C  4.48 
Time of reconstitution 50–60 second 
Angle of repose 33.690±0.112 







Carr’s index 11.33% 
*Results were expressed as (mean±SD, n=3). 
 
 
Fig. 1: FT-IR spectra of 95% ethanol extract of M. oleifera leaves (ME) and prepared Moringa granules (MG) 
 
Drug content of the prepared Moringa-G 
The drug content was determined using HPLC–UV method. The 
acceptance criterion of the initial concentration of the selected 
reference markers was 90%–110%. The percent drug contents for 
the three reference markers, namely, cryptochlorogenic acid, 
isoquercetin and astragalin, were 100.326±1.783, 99.631±1.322 and 
97.406±1.392, respectively, which were equivalent to 3.555, 19.593 
and 5.611 mg/g dry extract, respectively.  
In vitro dissolution test for the prepared Moringa-G 
The dissolution test of the preparedness Moringa-G revealed an 
improved dissolution rate and extent compared with the crude M. 
oleifera extract (fig. 2). The prepared Moringa granules showed 
increase in dissolution rate of cryptochlorogenic acid, isoquercetin 
and astragalin by 0.66, 1.34 and 1.23 folds respectively.  
This improvement in the dissolution profile could be due to the 
surfactant agent (Tween 20) adopted in the formula. Moreover, the 
gum Arabic fine powder used as an adsorbent and the formulation of 
M. oleifera extract as granules led to an increase in the surface area 
of the extract that exposed to the dissolution medium, thereby 
increasing the solubility. A low drug solubility is expected to yield a 
low dissolution rate. Based on the Noyes–Whitney law, the 
dissolution rate (dc/dt) is directly proportional to the concentration 
gradient (C0 − CX
  
) and surface area. 
 
Fig. 2: In vitro drug release profile and dissolution rate of three reference markers present in prepared Moringa granules. Ast= astragalin; 
CCA= cryptochlorogenic acid and Isoq= isoquercetin. Data were presented as mean±SD (n=6) 
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Microbial limit tests of Moringa-G 
Table (4) shows the microbial limit tests for the formulated 
Moringa-G which appeared to be free of any microbial 
contaminating. 
Heavy metals tests for Moringa-G 
Heavy metals, including arsenic, cadmium, lead and mercury, in the 
formulated Moringa-G were determined through [7]. The results 
revealed a non-detectable level of testing heavy metals in the 
formulations (table 5). Hence, the suitability and safety of the 
formulated Moringa-G were confirmed. 
In vivo anti-inflammatory assay 
Animals in the groups treated orally with either indomethacin, 95% 
ethanol extract of M. oleifera leaves, or Moringa-G significantly 
inhibited the increase in the paw thickness (P<0.05) compared with 
those in the control group (fig. 3). The oral administration of the 
95% ethanol extract of M. oleifera leaves showed less significant 
inhibition effect on the increase in the paw thickness (P<0.05) than 
Moringa-G. The effect of Moringa-G was comparable with that of 
indomethacin in terms of the extent and onset of activity. The oral 
administration of crude M. oleifera extract or Moringa-G began 2 h 
post-injection and continued until hour 5 post-injection. 
Formulation of Moringa crude extract as a granule lead up to 
improvement of the anti-inflammatory activity.  
The higher extent of activity and the faster onset of action of 
Moringa-G than those of the crude M. oleifera extract were attributed 
to the effects of the formulation of the extract in its pharmaceutical 
dosage form. Formulating M. oleifera extract as granules led to 
higher solubility and enhanced absorption and bioactivity compared 
with crude M. oleifera extract. Finding of [18], who formulated 
aqueous M. oleifera leaf extract as film dressing for wound healing, 
and [19], who formulated M. oleifera leaf powder as tablet, reported 
improvements in the in vivo bioactivity of the extract after 
formulation.
  
Table 4: Microbial limit tests for the formulated Moringa granules 
Microbial type Result Limit Method 
Total aerobic microbial count (TAMC) 
Total combined yeasts/moulds count (TYMC) 
Bile-tolerant gram-negative bacteria 
Salmonella sp. 
Escherichia coli  
Staphylococcus aureus  











in 10 g 
in 1 g 
in 1 g 
in 1 g 
BP 2013, Appendix XVIB 
BP 2013, Appendix XVIB 
BP 2013, Appendix XVIB 
 
BP 2013, Appendix XVIB 
BP 2013, Appendix XVIB 
BP 2013, Appendix XVIB BP 2013, Appendix XVIB 
*ND: not detected and BP: British Pharmacopoeia 
 
Table 5: Heavy metals tests for detection of arsenic, cadmium, lead and mercury levels in the formulated Moringa granules 







BP 2013, Appendix IID, ICP-AES 







BP 2013, Appendix IID, ICP-AES 
BP 2013, Appendix IID, ICP-AES 
*ND: not detected and BP: British Pharmacopoeia. 
 
 
Fig. 3: Effect of oral administration of 95% ethanol M. oleifera leaves, indomethacin, and Moringa granules on carrageenan-induced hind 
paw oedema in rats. a: significant difference at P<0.05 and b: significant difference at P<0.01. Data were presented as mean±SEM for 
number of animals n=6 
 
Effect of formulated Moringa-G on the paw thickness of rats  
Oral administration of indomethacin, 95% ethanol extract of M. 
oleifera leaves, and Moringa-G significantly inhibited the increase in 
the paw thickness of rats with CFA-induced arthritis (P<0.05) 
compared with that in the CFA-control group (fig. 4). Based on 
statistical data analysis, the effect of Moringa-G was comparable 
with that of indomethacin. Furthermore, Moringa-G was generally 
more effective in inhibiting the increase in the paw thickness than 
Moringa crude extract. 
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Fig. 4: Effect of oral administration of indomethacin, 95% ethanol extract of M. oleifera leaves, and Moringa granules on percent increase 
in paw thickness for CFA-induced arthritis rats. a: significant difference at P<0.05 and b: significant difference at P<0.01. Data were 
presented as mean±SEM for number of animals (n)=6 
 
Effect of Moringa-G on the body weight of rats  
Oral administration of 95% ethanol extract of M. oleifera leaves 
significantly increased the body weight of the animals (P<0.05) 
compared with that in the CFA-control group (fig. 5). Oral administration 
of indomethacin at 2.5 mg/kg/day and Moringa-G at dose equivalent to 
250 mg/kg/day increased the body weight, but the effect was not 
significant. Rats in the normal group showed a steady increase in body 
weight. Rats in the group orally treated with crude M. oleifera extract 
showed higher percent weight gain than those in the normal group.  
This result could be due to the high nutritional value and contents of 
essential amino acids and vitamins in the M. oleifera leaf extract. The 
insignificant increase in the body weight of rats in the group treated 
orally with indomethacin may be due to the adverse ulcerative and 
gastric disturbance effects associated with indomethacin [19]. For 
the rats treated with Moringa-G, the decrease in the body weight at 
the first 6 d, and the insignificant increase could be due to the effect 
of gum Arabic in reducing body weight and fat level [21]. 
Arthritic index 
Oral administration of indomethacin at 2.5 mg/kg/day, 95% ethanol 
extract of M. oleifera leaves at dose 250 mg/kg/day, and Moringa-G 
at dose equivalent to 250 mg/kg/day significantly decreased the 
arthritic scores (P<0.05) compared with that in the CFA-control 
group (fig. 6). The animal group orally treated with Moringa-G 
achieved the lowest arthritic scores, i.e. less severe clinical signs of 
inflammation and arthritis, than the animal groups given with 
indomethacin and crude M. oleifera extract. 
  
 
Fig. 5: Effect of oral administration of indomethacin, 95% ethanol extract of M. oleifera leaves, Moringa granules on percent increase in 
body weight for CFA-induced arthritis rats. a: significant difference at P<0.05 and b: significant difference at P<0.01. Data were presented 
as mean±SEM for number of animals (n)=6 
 
 
Fig. 6: Effect of oral administration of indomethacin, 95% ethanol extract of M. oleifera leaves, and Moringa granules on arthritic index of 
CFA-induced immunological arthritis rats. a: significant at P<0.05 and b: significant at P<0.01. Data were presented as mean±SEM for 
number of animals (n)=6 
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Walking track analysis using deMedinaceli method 
Rats with CFA-induced arthritis treated orally with indomethacin at 
2.5 mg/kg/day, 95% ethanol extract of M. oleifera leaves at 250 
mg/kg/day, and Moringa-G at dose equivalent to 250 mg/kg/day 
exhibited functional index within the normal range (±11%) on day 
21 (table 6). However, the CFA-control group showed an out of 
normal values after 3 w of CFA injection. Hence, Moringa-SD 
prevented the disruption of locomotion and gait behaviour. 
X-ray radiography assessment 
In the CFA-control group, soft tissue swelling (white arrows) and 
reduced joint spaces (black arrows) were observed, indicating the 
narrowing of the joint space under arthritic conditions (fig. 7). The 
average radiographic score for the CFA-control group (n=6) on day 
22 post CFA injection was 9.66±1.16. Groups given indomethacin at 
2.5 mg/kg/day, 95% ethanol extract of M. oleifera leaves at dose of 
250 mg/kg/day, and Moringa-G at dose equivalent to 250 
mg/kg/day for 21 d exhibited average  radiographic scores of 
3.17±1.08, 3.23±1.21, and 3.30±1.24, respectively. Statistical data 
 analysis of the obtained scores (mean±SEM) revealed that 21 d of 
oral treatment with  indomethacin, 95% ethanol extract of M. oleifera 
leaves, formulated Moringa-G  significantly reduced (P<0.01) the 
radiographic score of rats with CFA-induced arthritis. 
Haematology profile 
All of the animals in the treatment groups and the normal control 
group were evaluated for haematological parameters including the 
HGB, total RBC, %PCV, total WBC and ESR (table 7). The erythrocyte 
profile of rats in the CFA-control group was below the normal value 
ranges. These abnormal results suggest the occurrence of iron 
deficiency anaemia, which is a clinical manifestation of RA. The 
erythrocyte profiles of rats in all of the orally treated groups were 
comparable with those in the normal group but significantly 
different (P<0.05) from those in the CFA-control group. These 
results could be due to enhanced solubility of phytonutrients in the 
M. oleifera extract and the consequent improvement in absorption. 
  
Table 6: Effects of oral administration of indomethacin 2.5 mg/kg/d, 95% ethanol extract of M. oleifera leaves 250 mg/kg/d, and Moringa 
granules on functional index of CFA-induced arthritis rats 
Group Day 0 Day 14 Day 21 
CFA-control 1.67±1.51 -1.41±1.99 -18.22±6.19 
Indomethacin -4.11±1.92 -1.55±6.12 -5.88±2.60 
M95%E -1.80±4.43 -3.06±4.27 -1.38±3.87 
Moringa granules 2.23±2.45 -16.55±2.78 -7.89±2.16 
*Results were expressed as (mean±SEM, n=6). 
 
 
Fig. 7: X-ray radiographs for hind paws of CFA-induced arthritis rats at day 22 post CFA injection. 1: CFA-induced arthritis rat without 
treatment, 2: animal orally treated with indomethacin at dose 2.5 mg/kg/day, 4: animal orally treated with 95% ethanol extract of M. 
oleifera leaves at dose 250 mg/kg/day and 5: animal orally treated with Moringa granules at dose equivalent to 250 mg/kg/day 
 
Table 7: Effects of oral administration of indomethacin, 95% ethanol extract of M. oleifera leaves, and formulated Moringa granules on 
haemoglobin content (HGB), total red blood cell count (RBC), % packed cell volume (%PCV), total white blood cells count (WBC) and 
erythrocyte sedimentation rate (ESR) in CFA-induced arthritis rats; results were expressed as mean±SEM and n=6 
Haematology 
parameter 
Normal range Animal group 
Healthy rats CFA-Control Indomethacin M95%E MG 
HGB (g/dl) 13.5-18.4 13.60±0.15* 12.25±0.79 a 13.30±0.45 13.87±0.36a 13.65±0.74b a 
PCV (%) 38.9-54.9 39.50±0.01* 35.75±0.02 a 39.50±0.02 41.0±0.01a 39.75±0.17b 
RBC (10[12]/l) 
a 
7.8-10.2 7.86±0.09* 7.08±0.39 b 7.83±0.37 7.95±0.23a 7.62±0.25a 
WBC (10
a 
9 5.9-19.0/l) 9.70±2.19* 12.59±0.54 a 7.75±1.22 9.76±0.74 b 10.48±0.24 
ESR (mm/h) 0.5-1.45 1.12±0.13** 2.04±0.04 a 0.45±0.05 0.84±0.12b 1.01±0.09b b 
MG: Moringa granules; M95%E: 95% ethanol extract of M. oleifera leaf; *: normal range in rats according to Petterino and Argentino-Storino (2006); 
**: normal range in rats according to Ihedioha et al. (2017); a: significant at P<0.05 and b: significant at P<0.01 compared to CFA-control group, * 
Results were expressed as (mean±SEM, n=6). 
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The CFA-control group showed the highest WBC level, which is still 
within the normal range. The groups orally given indomethacin at 
2.5 mg/kg/day showed a significant difference (P<0.05) in WBC 
compared with the CFA-control group. By contrast, the oral 
administration of crude extract of M. oleifera leaves and Moringa-G 
at dose equivalent to 250 mg/kg/day did not significantly affect the 
WBC compared with that in the CFA-control group.  
Rats with CFA-induced arthritis treated orally with indomethacin at 
2.5 mg/kg/day, 95% ethanol extract of M. oleifera leaves at 250 
mg/kg/d, or Moringa-G at dose equivalent to 250 mg/kg showed 
significant decreases in the ESR (P<0.05) compared with rats in the 
CFA-control group. 
CONCLUSION 
In some cases processing of natural source products may effects on 
bioactivity of the final product, therefore, material processing was 
evaluated to ensure a consistent level of bioactivity. The main challenge 
in the formulation of herbal products is the complex nature of its 
constituents and the scarcity of fundamental information about the 
physical and chemical properties of plant extracts. The formulation of M. 
oleifera leaf extract as a standardised granule effectively improved their 
physical and chemical properties, particularly flowability, crystallinity 
degree, aqueous solubility, drug release profile and stability under stress 
conditions. In comparison with crude Moringa extract, the formulation of 
95% ethanol extracts of Moringa leaves as a common granules improved 
their in vivo bioactivity. Haematological tests, body weight gain and 
arthritic index also indicated that the admissibility and health 
improvement induced symptoms of arthritis could be alleviated by the 
formulated Moringa extract were better than those promoted by to a 
greater extent than crude Moringa extract. 
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